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Cutaneous malignant melanoma is an aggressive disease of poor prognosis. Clinical and experimental studies
have provided major insight into the pathogenesis of the disease, including the functional interaction between
melanoma cells and surrounding keratinocytes, fibroblasts, and immune cells. Nevertheless, patients with
metastasized melanoma have a very poor prognosis and are largely refractory to clinical therapies. Hence,
diagnostic tools to monitor melanoma development, as well as therapeutic targets, are urgently needed. We
investigated the expression pattern of the kallikrein-related peptidase 6 (KLK6) in human melanoma tissue
sections throughout tumor development. Although KLK6 was not detectable in tumor cells, we found strong
KLK6 protein expression in keratinocytes and stromal cells located adjacent to benign nevi, primary melanomas,
and cutaneous metastatic lesions, suggesting a paracrine function of extracellular KLK6 during neoplastic
transformation and malignant progression. Accordingly, recombinant Klk6 protein significantly induced
melanoma cell migration and invasion accompanied by an accelerated intracellular Ca2þ flux. We could
further demonstrate that KLK6-induced intracellular Ca2þ flux and tumor cell invasion critically depends on the
protease-activated receptor 1 (PAR1). Our data provide experimental evidence that specific inhibition of the
KLK6–PAR1 axis may interfere with the deleterious effect of tumor–microenvironment interaction and represent
a potential option for translational melanoma research.
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INTRODUCTION
The skin is the largest human organ, being composed of the
epidermis and dermis separated by the basement membrane.
The epidermis forms a stratified epithelium with several
layers of keratinocytes at different stages of differentiation.
Apart from keratinocytes, the interfollicular epidermis con-
tains melanocytes, which are located in the stratum basale.
Their proliferation and differentiation are regulated by cells of
their environment, especially the keratinocytes (Haass et al.,
2005). Keratinocytes regulate melanocyte functions through a
complex system of paracrine growth factors and cell–cell
adhesion molecules. Alteration of this homeostatic balance
can trigger a continuous proliferation of melanocytes support-
ing neoplastic transformation and may lead to the develop-
ment of melanoma (Haass et al., 2004). Human melanomas
are malignant and strongly pigmented tumors, the develop-
ment of which is divided into four steps: the dysplastic nevus,
primary melanoma in the radial and vertical growth phase,
and finally, metastatic melanoma (Hsu et al., 2002; Gaggioli
and Sahai, 2007). A prerequisite for malignant progression of
melanoma is the invasion of tumor cells in the surrounding
tissue, characterized by reduced cell–cell adhesion, enhanced
migration activity, and degradation of the extracellular matrix
(Kuphal et al., 2005). It is well accepted that tumor-induced
proteases are involved in all three processes (Hsu et al., 1996;
Kapadia et al., 2004; Shinoda et al., 2007).
Recently, enhanced expression of the kallikrein-related
peptidase 6 (Klk6) was identified in advanced tumor stages of
the chemically induced tumor model of mouse back skin,
and its human ortholog KLK6 was correlated with malignant
progression of human skin cancer (Breitenbach et al., 2001;
Klucky et al., 2007). KLK6 belongs to a large family of
KLKs, representing secreted chymotrypsin- and trypsin-like
serine proteases with diverse expression under physiological
and pathological conditions, including common types of
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human cancer (Yousef and Diamandis, 2001). Ectopic Klk6
expression in a mouse keratinocyte cell line induced spindle-
like cell morphology with impaired cell–cell adhesion and
accelerated cell proliferation, migration, and invasion
(Klucky et al., 2007). Alterations in keratinocyte cell
physiology were partly due to KLK6-induced E-cadherin
ectodomain shedding, which critically depends on the
presence of matrix-metalloprotease activity (Klucky et al.,
2007). Here we focused on KLK6 protein expression in the
development and progression of melanoma skin cancer and
investigated the impact of recombinant rat Klk6 protein on
human melanoma cell migration and invasion.
RESULTS
KLK6 expression during human melanoma development
To identify the KLK6 expression pattern, at distinct stages of
human melanoma development, human tissue sections
of dysplastic nevi (n¼10), primary melanoma (n¼ 11), and
metastatic melanoma (n¼12) were subjected to immuno-
histochemistry (IHC) analysis. KLK6 protein expression was
not detectable in tumor cells of primary and metastatic
melanoma, and specific KLK6 staining was also absent
from atypic melanocytes of dysplastic nevi (Supplementary
Figure S1 online and Figure 2). However, melanin produc-
tion in some of these cells hampered, at least in part, a final
conclusion. Hence, we confirmed the absence of KLK6
protein expression in atypic melanocytes of dysplastic nevi,
and tumor cells of primary and metastatic melanoma using
the red AECþ substrate chromogen for IHC staining
(Figure 1). Although KLK6 expression was absent in tumor
cells, both staining procedures revealed positive staining
for KLK6 protein expression in endothelial cells (Figure 1 and
Supplementary Figure S1 online). However, KLK6-positive
endothelial cells were not restricted to blood vessels within
the tumor or the adjacent tissue, but were also present
in dermal tissue of normal skin. KLK6 protein expression in
CD34-positive endothelial cells was further confirmed
by immunofluorescence analysis, whereas no coexpression
was detected for CD68-positive macrophages, CD45-positive
lymphocytes, CD1a-positive dentritic cells, or mast cells
(Supplementary Figure S2 online).
The most striking difference in KLK6 expression between
tissue sections of unaffected skin (no or weak staining) and
tumor samples was observed in keratinocytes adjacent to
tumor cells (Figures 1 and 2 and Supplementary Figure S1
online). Increased KLK6 staining in epidermal keratinocytes
was found in 6 (medium staining) and a strong KLK6 staining
in 5 out of 11 melanoma sections. Tumor cells were
identified using an anti-S100 antibody, a well-established
marker for melanoma cells. These data suggested that the
presence of melanoma cells or melanoma cell-derived
factors induce KLK6 expression in keratinocytes. In line
with this assumption, we observed enhanced KLK6 protein
levels in keratinocytes near metastatic melanomas growing
within the epidermis (epidermotropic metastasis; Figure 2a
and b), but not on tissue sections from metastatic melanomas
located in the dermis or subcutis (dermal metastasis;
Figure 2c–f).
KLK5 and KLK7 are two abundant KLKs in human skin that
are critically involved in skin barrier function and home-
ostasis, and part of a KLK proteolytic activation cascade (Eissa
and Diamandis, 2008). In contrast to increased KLK6
expression in keratinocytes adjacent to melanoma cells, we
found no major increase in KLK5 and KLK7 protein levels that
showed strong expression in terminally differentiated kerati-
nocytes of both unaffected skin and tumor tissue sections
(Supplementary Figure S3 online). However, we observed a
broadened expression pattern of KLK5 and KLK7 in the
epidermis of some tissue sections of epidermotropic metas-
tasis (Supplementary Figure S3 online).
In summary, the IHC analysis of tissue sections from
human melanoma patients indicate the existence of melano-
ma cell-derived factors, which may trigger molecular path-
ways in early stages of melanoma pathogenesis, resulting in
increased levels of KLK6 expression in adjacent keratino-
cytes, but not of other abundant KLKs in human epidermis.
Recombinant Klk6 induces cell migration and invasion of
human melanoma cells
Our findings that strong KLK6 expression in epidermal
keratinocytes is a characteristic feature of human melanoma
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Figure 1. Kallikrein-related peptidase 6 (KLK6) protein expression in human
melanoma tissue sections. Immunohistochemistry analysis with tissue
sections from dysplastic nevi (a, b), primary melanoma (SSM, c, d), and
metastatic epidermotropic melanoma (e, f) was performed with an anti-KLK6
antibody and revealed specific staining (red signal) in epidermal keratinocytes
(black arrowheads) and blood vessels (open arrowheads). Right panels
show a higher magnification of areas marked by black boxes. Sections
were counterstained with hematoxylin. Dashed lines mark the tumor
border. Bars¼ 40mm. Mel, melanoma; Met, metastasis; SSM, superficial
spreading melanoma.
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raised the hypothesis that enhanced levels of extracellular
KLK6 may contribute to neoplastic transformation and/or
malignant progression of melanoma cells. To test this
assumption and to identify potential tumor-relevant
processes affected by KLK6, we treated two established
human melanoma cell lines, MeWo and SKmel23, with
recombinant rat Klk6 protease. Measuring cell proliferation
by quantification of BrdU incorporation using FACS analysis
revealed no significant induction of BrdU-positive MeWo or
SKmel23 melanoma cells upon Klk6 stimulation (Supple-
mentary Figure S4 online), demonstrating that the protease
does not affect melanoma growth by induction of tumor cell
proliferation.
Next, we determined tumor cell migration in the presence
or absence of recombinant rat Klk6 protein using a scratch
wounding assay. We observed a significant increase in
MeWo and SKmel23 cell migration 12 hours post Klk6
addition compared with control cells that persisted until 48
or 96 hours, respectively (Figure 3a and b). The invasion
capacity of control and Klk6-treated SKmel23 cells was
additionally examined in a Matrigel invasion assay. Quanti-
fication of fluorescent-labeled tumor cells revealed a signifi-
cantly enhanced invasion capacity of Klk6-treated SKmel23
cells in comparison with untreated controls (Figure 3c).
Recombinant Klk6 regulates protease-activated receptor
signaling and Ca2þ release in melanoma cell lines
To identify the mechanism of how KLK6 promotes melanoma
cell migration and invasion, we focused on the recently
described function of KLK6 as an endogenous activator of
protease-activated receptors (PARs) (Angelo et al., 2006;
Oikonomopoulou et al., 2006). PARs are G-protein-coupled
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Figure 2. Kallikrein-related peptidase 6 (KLK6) protein expression in human
metastatic melanoma. Immunohistochemistry analysis was performed as
described in Figure 1 and revealed strong KLK6 expression in keratinocytes
adjacent to metastatic epidermotropic melanoma (a, b), but not in samples of
metastatic dermal melanoma (c–f). Dashed lines mark the tumor border and
KLK6 expression in blood vessels is indicated by open arrowheads.
Bars¼ 40 mm. Met, metastasis. Right panels show a higher magnification of
areas marked by black boxes.
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Figure 3. Recombinant kallikrein-related peptidase (Klk6) induces
melanoma cell migration and invasion. Relative migration of MeWo (a) and
SKmel23 (b) cells was quantified in a scratch wounding assay at indicated
time points. The distance between two migrating cell borders was measured,
and relative migration is indicated in percentage with closed wounds set
to 100%. Black bars represent untreated cells and white bars indicate cells
treated with 40 nM recombinant rat Klk6. (c) Relative invasion of SKmel23
cells was measured using BD BioCoat Matrigel invasion chambers. Invading
Klk6-treated (Klk6) and untreated cells (control) were stained with calcein
fluorescent dye and measured with the BMG FLUOSTAR Optima device.
The number of invading cells in a control experiment was set to one and
relative invasion capacity was determined. *Po0.05; **Pp0.007;
***Po0.0005.
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receptors that trigger numerous cellular responses, including
intracellular Ca2þ release in response to extracellular
protease activity (Steinhoff et al., 2005). We focused our
analysis on PAR1 as high expression was shown on tumor
cells of human melanoma lesions and PAR1 seems to
contribute to the acquisition of the malignant phenotype by
facilitating tumor cell invasion and metastasis (Melnikova
et al., 2008). Indeed, PAR1 expression was detectable in
various melanoma cell lines as measured by western blot and
FACS analysis (Figure 4a and b). For further analysis,
SKmel23 cells were used because of the described low-
invasive phenotype in vitro and in vivo (Klose et al., 2006).
Stimulation of SKmel23 cells with a PAR1-specific agonist
peptide (TFLLRamide) revealed a strong increase in intracel-
lular Ca2þ flux, which was monitored by FACS analysis
(Figure 4c). A comparable increase in intracellular Ca2þ flux
was also measured after treatment of SKmel23 cells with
recombinant rat Klk6 (Figure 4d), suggesting that accelerated
tumor cell migration and invasion is, at least in part, mediated
by KLK6-induced PAR1 signaling.
To test the impact of PAR1 signaling on KLK6-mediated
tumor cell migration and invasion, we silenced PAR1
expression in SKmel23 cells using a lentiviral small hairpin
RNA (shRNA) strategy. Efficient downregulation of PAR1
expression was confirmed for SKmel23 cells infected with
shRNA2152 (SKmel23#1 and SKmel23#2) by quantitative
reverse transcription-PCR, western blot, and FACS analysis
(Figure 5a–c). In contrast, SKmel23 cells infected with
shRNA1349 (SKmel23#3) or a scrambled shRNA (SKmel23#4)
showed comparable PAR1 transcript and protein levels
(Figure 5 and data not shown) and were used as controls
for further experiments. Finally, Ca2þ flux measurement after
treatment with TFLLRamide confirmed impaired PAR1
activation in SKmel23#1 and SKmel23#2 compared with
control cells (Figure 5d and data not shown).
Treatment of PAR1-downregulated cells (SKmel23#1 and
SKmel23#2) with recombinant rat Klk6 protein revealed an
almost complete loss of intracellular Ca2þ flux and impaired
tumor cell invasion compared with control cells (Figure 6).
Finally, we performed a co-IHC staining on human primary
melanoma and metastatic epidermotrophic melanoma sec-
tions and could confirm PAR1 protein expression in
melanoma cells and KLK6 protein expression in adjacent
epidermal keratinocytes (Figure 6d).
In summary, these data strongly suggest that the KLK6-
PAR1 axis contributes to the active interaction between
melanoma cells and their microenvironment and supports
malignant progression by inducing melanoma cell invasion.
DISCUSSION
Kallikreins are implicated in a vast range of normal and
pathological conditions, in which they either function
independently or as part of proteolytic cascades (Borgono
and Diamandis, 2004). Accumulating evidence supports the
notion that human tissue Kallikreins, the concentrations of
which are often abnormal in common human malignancies,
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Figure 4. Protease-activated receptor 1 (PAR1) expression and Ca2þ release
in melanoma cell lines. (a) Western blot analysis of whole-cell lysates with an
anti-PAR1 antibody. b-Actin protein levels served as control for cell extract
quantity and quality. (b) FACS measurement of PAR1 receptor expression at
the SKmel23 cell surface (white) in comparison with control staining with the
secondary antibody (black). (c, d) Intracellular calcium levels were assessed
by FACS analysis using the calcium-indicative dyes fluo-4 and FuraRed.
One representative measurement (n¼ 3) of calcium release after stimulation
with 1 mgml1 ionomycin and 100 mM of PAR1 (TFLLRamide) is shown in c.
Calcium release after stimulation with 1 mgml1 ionomycin and 40nM
recombinant rat Klk6 is shown in d. The arrows indicate treatment with
the stimulus.
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Figure 5. Protease-activated receptor 1 (PAR1) silencing in SKmel23 cells.
(a) Relative PAR1 transcript levels in SKmel23 #1–4 cells were analyzed using
real-time reverse transcription-PCR. All expression levels were normalized
to lamin B1 transcript levels. (b) Western blot analysis of a whole-cell lysate
using anti-PAR1 antibody. b-Actin protein levels served as control for cell
extract quantity and quality. (c) FACS measurement to quantify PAR1 receptor
expression at the cell surface of SKmel23 cells (#2 white and #3 gray).
(d) Calcium measurement was recorded as described in Figure 4. One
representative (n¼ 3) measurement of calcium release is shown in PAR1
knockdown SKmel23 cells (#2) in comparison with control SKmel23 cells (#3)
upon stimulation with 100mM of PAR1 agonistic peptide (TFLLRamide). The
arrow indicates treatment with the stimulus. ShRNA, small hairpin RNA.
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not only have prognostic and diagnostic value in various
types of cancer but also contribute to tumor pathogenesis
(Borgono and Diamandis, 2004; Obiezu and Diamandis,
2005). However, little attention has been paid to their
expression and involvement in the development and malig-
nant progression of human melanoma, the leading cause of
skin cancer mortality worldwide. In the past, Winnepen-
ninckx et al. (2006) identified a 254-gene signature by gene
expression profiling, including KLK4, KLK7, and KLK11,
which is associated with metastatic dissemination and overall
survival of patients with primary melanoma. More recently,
KLK6 and KLK7 protein expressions were analyzed in human
nevi and primary melanoma tissue sections, and both protein
levels were higher in melanomas than in common nevi
(Rezze et al., 2011). In line with this data, we found
enhanced KLK6 transcript levels in malignant melanoma
compared with unaffected skin samples (Klucky et al., 2007).
However, the detailed immunohistochemical analyses on
human melanoma tissue sections shown in this study
demonstrate that enhanced KLK6 levels are not due to
expression in melanoma cells, but rather due to its expression
in adjacent keratinocytes and endothelial cells within the
tumor microenvironment. These data suggest the presence of
one or several tumor cell-derived factors that induce aberrant
KLK6 expression in adjacent keratinocytes. However, we
cannot exclude the possibility that induced KLK6 expression,
which is most prominent in differentiated keratinocytes, is at
least in part also due to aberrant epidermal homeostasis.
It is well established that melanoma cells actively interact
with the tumor microenvironment by the secretion of a range
of growth factors, cytokines, and chemokines, and thereby
modulate the malignant phenotype (Lee and Herlyn, 2007).
These soluble factors could affect intracellular signaling
pathways in adjacent keratinocytes that are known to activate
KLK6 transcription in epithelial cells, such as ERK-,
PI3K-, and AKT-dependent cascades (Bourcier et al., 2006;
Henkhaus et al., 2008a, b). Analysis of KLK6 expression in
coculture experiments with human keratinocyte and
melanoma cells should unravel the existence of a melanoma
cell-derived soluble factor.
The establishment of an inflammatory microenvironment
that is often observed at the site of tumors, including
melanoma, could also contribute to the enhanced KLK6
expression in adjacent keratinocytes. In line with this
assumption, we demonstrated induced expression of the
murine ortholog of human KLK6 in epidermal keratinocytes
after stimulation with the phorbol ester 12-O-tetradecanoyl-
phorbol-13-acetate, a potent inducer of skin inflammation
(Breitenbach et al., 2001). Moreover, significantly higher
levels of KLK6 were described in keratinocytes of psoriasis
and other inflammatory skin disorders (Komatsu et al., 2005,
2007). It is worth noting that KLK6 is often coexpressed with
other Kallikrein family members, some of which can activate
the KLK6 proenzyme by proteolytic cleavage (Blaber et al.,
2007; Yoon et al., 2007). Although KLK5 and KLK7 are
expressed by epidermal keratinocytes and have a pivotal role
in the process of skin desquamation (Ovaere et al., 2009),
their function in human melanoma development and
progression has not been addressed so far.
Although the physiological function of KLK6 has been only
partly elucidated, clinical studies and experimental
model systems provide compelling evidence for its critical
role in neoplastic transformation and malignant progression
(Borgono and Diamandis, 2004). Recently, we showed that
KLK6 induces E-cadherin ectodomain shedding, thereby
interfering with cell–cell adhesion and supporting migra-
tion and invasion of keratinocytes (Klucky et al., 2007).
E-cadherin is a key factor that mediates direct cell–cell
adhesion between epidermal keratinocytes and melanocytes,
which is pivotal for normal growth and behavior of
melanocytes in the state of homeostasis. Melanoma cells
escape from the control of keratinocytes through several
mechanisms, including downregulation of E-cadherin
expression and function (Haass et al., 2005). Hence, it is
tentative to speculate that increased KLK6 expression by
keratinocytes may promote malignant progression due to
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Figure 6. Impaired calcium release and invasion after kallikrein-related
peptidase 6 (Klk6) stimulation in protease-activated receptor 1 (PAR1)-
silenced SKmel23 cells. (a) Calcium measurement was recorded as described
in Figure 4. One representative measurement of calcium release is shown in
PAR1 knockdown SKmel23 cells (#2) in comparison with control SKmel23
cells (#3) upon stimulation with 40 nM recombinant rat Klk6. The arrow
indicates treatment with the stimulus. (b, c) Invasion assay was performed as
described in Figure 3. Relative invasion capacity of Klk6-treated (Klk6) and
control PAR1 knockdown SKmel23 cells (#2; b) and SKmel23 control cells
(#3; c) is shown. *Po0.05. (d) Coimmunohistochemistry analysis with tissue
sections from unaffected skin, primary melanoma (SSM), and metastatic
epidermotropic melanoma specimens was performed with an anti-KLK6
antibody (green signal) and an anti-PAR1 antibody (red signal). Sections were
counterstained with hematoxylin. Bar¼ 200 mm. Mel, melanoma; Met,
metastasis; SSM, superficial spreading melanoma.
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functional inactivation of cell–cell adhesion by E-cadherin
during early stages of melanoma development.
Stimulation of human melanoma cells with recombinant
Klk6 protein revealed a significant increase in tumor cell
migration and invasion, accompanied by accelerated intra-
cellular Ca2þ flux. Recent studies highlighted the fact that
KLK6 evokes intracellular Ca2þ flux by the activation of PARs
(Angelo et al., 2006; Oikonomopoulou et al., 2006; Vandell
et al., 2008). Several clinical and experimental observations
suggested that PAR1 contributes to the acquisition of the
malignant phenotype by facilitating tumor cell invasion
and metastasis (Arora et al., 2007; Melnikova et al., 2008):
(i) PAR1 overexpression was found predominantly in
malignant melanoma and in metastatic lesions (Massi et al.,
2005; Tellez et al., 2007; Depasquale and Thompson, 2008),
(ii) PAR1 expression correlated with the metastatic potential
of melanoma cell lines (Blackburn et al., 2009; Melnikova
et al., 2009; Villares et al., 2009), and (iii) inhibition of PAR1
expression in a human melanoma xenograft model inhibited
tumor growth and metastasis (Tellez and Bar-Eli, 2003; Tellez
et al., 2003; Villares et al., 2008). In line with the assumption
that KLK6 may promote malignant progression of melanoma
by activation of PAR1, its silencing in melanoma cells
impaired both KLK6-induced intracellular Ca2þ flux and
invasion. However, the role of intracellular Ca2þ signaling in
melanoma development and malignant progression is not
well established, and several other signaling cascades have
been described downstream of PAR1 signaling, which are
critically involved in tumorigenesis, such as activation of
mitogen-activated protein kinases (Steinhoff et al., 2005;
Villares et al., 2011). Indeed, we found an increase in the
activation of ERK1/2 and p38 MAPKs upon treatment of
SKmel23 cells with recombinant rat Klk6, which was
determined by western blot analysis with phospho-specific
antibodies, whereas JNK1/2 signaling seems to be unaffected
(data not shown). Although ERK1/2- and p38 MAPK-signaling
pathways exert several key functions in melanoma cell
development and progression, including tumor cell migration
and invasion, more detailed analysis will be required in the
near future to unravel the role of both signaling cascades in
the KLK6-mediated cross-talk between melanoma cells and
its microenvironment.
In summary, our data provide experimental evidence for a
potent role of extracellular KLK6 in neoplastic transformation
and malignant progression of human melanoma. Further
investigations focusing on the regulation of KLK6 expression
and its impact on molecular pathways, such as PAR signaling,
will certainly contribute to a better understanding of the
molecular nature of melanoma development. Finally, it will
be a major challenge for the future to test the concept
whether specific inhibition of KLK6 expression and/or func-
tion could be used as a novel strategy for translational cancer
research.
MATERIALS AND METHODS
Human skin biopsies
Skin biopsies from patients with melanoma were obtained from
surgical excisions of the affected areas at the Department of
Dermatology, University of Cologne. The patients signed the
informed consent from the Department of Dermatology, University
of Cologne, approved by the Institutional Commission of Ethics
(Az. 9645/96). The study was conducted according to Declaration
of Helsinki Principles. Staging of primary melanomas that were used
in this study is given in Supplementary Table S1 online.
Immunohistochemistry analysis and scoring
For IHC analysis, paraffin sections were stained according to the
manufacturer’s instructions (Vectastain Elite ABC Kit and ImmPRESS
Kit, Vector Laboratories, Lo¨rrach, Germany). Primary and secondary
antibodies are listed in Supplementary Table S2 online.
As substrates, we used liquid DABþ Substrate or AECþ Substrate
Chromogen (Dako, Hamburg, Germany), or VectorRed and Histo-
green (Vector Laboratories). All tissue sections were counterstained
with hematoxylin (AppliChem, Darmstadt, Germany).
Scoring of tumor samples was based on the signal intensity and
abundance in keratinocytes adjacent to the tumor tissue (score 1¼ no
or weak staining; score 2¼medium staining; score 3¼ strong staining),
and according to the staining in keratinocytes of the epidermis in
control and unaffected skin (score 1¼ no or weak staining).
Cell lines, culture conditions, and PAR1 silencing
Human melanoma MeWo cells were cultured in DMEM medium
(PAA, Pasching, Austria); human SKmel23 and SKmel28 melanoma
cells were cultured in Roswell’s Park Memorial Institute medium
(PAA); and HEK293T cells were cultured in IMEM medium
(Invitrogen, Karlsruhe, Germany). Culture medium was supplemen-
ted with 10% fetal calf serum, 2mM glutamin (PAA), 100Uml1
penicillin, and 0.1mgml1 streptomycin (PAA), and the cells were
cultured at 37 1C in a humidified atmosphere of 8% CO2.
Lentiviral particles were produced by transient co-transfection of
specific shRNA vectors (listed in Supplementary Table S3 online)
with pMDLg-pRRE and pRSV-REV packaging vectors, and the
pMD2-VSVG envelope vector in HEK293T cells. pMDLg-pRRE and
pRSV-REV packaging vectors, as well as the pMD2-VSVG envelope
vector, were kindly provided by Dr Luigi Naldini (San Raffaele
Telethon Institute for Gene Therapy, University Medical School,
Italy). For the transfection of one dish, 12.5 mg of pMDLg-pRRE
plasmid, 6.25 mg of pRSV-REV, 9mg of pMD2-VSVG, and 32 mg of
shRNA vector was mixed in 1ml OPTIMEM medium (Invitrogen,
Karlsruhe, Germany) containing 179.25mgml1 polyethylenimine.
After 30minutes of incubation at room temperature, the transfection
mixture was added to the cells. At 24 hours after transfection, the
virus was purified by ultracentrifugation for 2 hours at 20 1C.
For lentiviral transduction, 1 104 SKmel23 cells were seeded in
a 48-well plate and transduced with lentiviral particles. After 3 days,
transduced cells were selected with puromycin (0.5 mgml1) for 1
week.
Scratch wounding assay
MeWo and SKmel23 cells were seeded in a 12-well plate and
cultured for 24 hours to reach confluency. Cells were treated
with 10 mgml1 mitomycin C (Sigma, Taufkirchen, Germany) for
1 hour and washed intensively with PBS. Subsequently, the cell
monolayer was scratched with a micropipette tip, and cells were
cultivated in the absence or presence of 40 nM recombinant rat Klk6
(Blaber et al., 2002). Images were taken at indicated time points
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using light microscopy and a digital camera (Olympus, Hamburg,
Germany). The distance between the migration fronts was measured
using the UTHSCSA Image tool software (http://ddsdx.uthscsa.edu/
dig/itdesc.html).
Cell invasion assay
The cell invasion assay was performed according to the manufac-
turer’s instructions of the BD BioCoat Matrigel Invasion chamber for
24 wells (BD Biosciences, Heidelberg, Germany). SKmel23 cells
(150,000 cells) were seeded in the insert and incubated for 2 hours.
Subsequently, 40 nM recombinant rat Klk6 (Blaber et al., 2002) was
added and cell invasion was measured after 48 hours. Cells
were stained with 4 mgml1 Calcein BD AM Fluorescent Dye
(BD Biosciences) in HPBS for 1 hour at 37 1C. The measurement was
recorded using the BMG FLUOSTAR Optima device (BMG Labtech,
Offenburg, Germany) with the bottom reading optic.
RNA isolation and quantitative reverse transcription-PCR
RNA was isolated using Pure Link RNA Mini Kit (Invitrogen) and
reverse transcribed as described previously (Gebhardt et al., 2008).
Quantitative reverse transcription-PCR reactions were performed
with equal amounts of cDNA using the AbiPrism 7000 Sequence
Detection System (Applied Biosystems, Foster City, CA) in a volume
of 30 ml using the Platinum SYBR Green qPCR SuperMix from
Invitrogen. Primers are listed in Supplementary Table S4 online.
Protein isolation and western blot analysis
Protein isolation and western blot analysis were performed
as described previously (Klucky et al., 2007). Antibodies are listed
in Supplementary Table S2 online.
FACS analysis
For detection of membrane proteins by FACS analysis, melanoma cells
were detached from the cell culture dish using accutase (PAA).
Subsequently, 5 105 cells were washed once with PBS and stained
with the primary antibody diluted in 200ml PBS/1% BSA for 30minutes
at room temperature. After three washing steps, the cells were
incubated with the secondary, fluorescence-labeled antibody for
30minutes on ice and protected from light. Afterward, the cells were
washed three times and measured with the FACSCalibur (BD
Biosciences). Antibodies are listed in Supplementary Table S2 online.
Measurements of intracellular calcium release
For measurements of intracellular calcium release, SKmel23 cells
were incubated for 1 hour at 37 1C with the calcium-sensitive dyes
Fluo-4 and FuraRed (Invitrogen). Cells were resuspended in
Roswell’s Park Memorial Institute medium without fetal calf serum.
During flow cytometry-based calcium measurement (FACSCalibur;
BD Biosciences), SKmel23 cells were stimulated by the addition of
1mgml1 ionomycin (Invitrogen), 100 nM of PAR1 agonistic peptide
TFLLR (Bachem, Bubendorf, Switzerland), 100 nM of PAR2 agonistic
peptide SLIGKV (Bachem), or 40 nM recombinant rat Klk6 (Blaber
et al., 2002). The fold calcium increase was determined by using
FCSpress and FlowJo software (Tree star, Ashland, OR).
Cell proliferation assay
The cell proliferation assay was performed using the APC BrdU Flow
Kit (BD Biosciences) according to the manufacturer’s instruction.
Statistical procedures
Result represents three independent experiments, which were
conducted in triplicates. Statistical data analysis was performed
with a t-test using GraphPad PRISM version 4 software (GraphPad,
San Diego, CA). Bars represent mean values±SEM.
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